Manufacturer of Controlled Substances Registration: Patheon Pharmaceuticals, Inc., 46604 [2015-19173]

Download as PDF 46604 Federal Register / Vol. 80, No. 150 / Wednesday, August 5, 2015 / Notices Background The Commission, pursuant to section 751(c) of the Tariff Act of 1930 (19 U.S.C. 1675(c)), instituted this review on March 2, 2015 (80 FR 11226) and determined on June 5, 2015 that it would conduct an expedited review (80 FR 37661, July 1, 2015). The Commission completed and filed its determination in this review on July 30, 2015. The views of the Commission are contained in USITC Publication 4546 (July 2015), entitled Hand Trucks and Certain Parts Thereof from China: Investigation No. 731–TA–1059 (Second Review). BILLING CODE P DEPARTMENT OF LABOR [FR Doc. 2015–19080 Filed 8–4–15; 8:45 am] BILLING CODE 7020–02–P Office of the Secretary Agency Information Collection Activities; Submission for OMB Review; Comment Request; Application for a Farm Labor Contractor or Farm Labor Contractor Employee Certificate of Registration DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Manufacturer of Controlled Substances Registration: Patheon Pharmaceuticals, Inc. 16:54 Aug 04, 2015 Jkt 235001 Notice. The Department of Labor (DOL) is submitting the Wage and Hour Division (WHD) sponsored information collection request (ICR) revision titled, ‘‘Application for a Farm Labor Contractor or Farm Labor Contractor Employee Certificate of Registration,’’ to the Office of Management and Budget (OMB) for review and approval for use in accordance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C. 3501 et seq.). Public comments on the ICR are invited. DATES: The OMB will consider all written comments that agency receives on or before September 4, 2015. ADDRESSES: A copy of this ICR with applicable supporting documentation; including a description of the likely respondents, proposed frequency of response, and estimated total burden may be obtained free of charge from the RegInfo.gov Web site at http:// www.reginfo.gov/public/do/ PRAViewICR?ref_nbr=201505-1235-001 (this link will only become active on the day following publication of this notice) or by contacting Michel Smyth by telephone at 202–693–4129, TTY 202– 693–8064, (these are not toll-free numbers) or sending an email to DOL_ PRA_PUBLIC@dol.gov. Submit comments about this request by mail or courier to the Office of Information and Regulatory Affairs, SUMMARY: Patheon Pharmaceuticals, Inc. applied to be registered as a manufacturer of a certain basic class of controlled substance. The Drug Enforcement Administration (DEA) grants Patheon Pharmaceuticals, Inc. registration as a manufacturer of this controlled substance. SUPPLEMENTARY INFORMATION: By notice dated March 9, 2015, and published in the Federal Register on March 24, 2015, 80 FR 15632, Patheon Pharmaceuticals, Inc., 2110 E. Galbraith Road, Cincinnati, Ohio 45237 applied to be registered as a manufacturer of a certain basic class of controlled substance. No comments or objections were submitted for this notice. The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Patheon Pharmaceuticals, Inc. to manufacture the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing the company’s physical security systems, verifying the company’s SUMMARY: asabaliauskas on DSK5VPTVN1PROD with NOTICES ACTION: Notice of registration. VerDate Sep<11>2014 Dated: July 29, 2015. Joseph T. Rannazzisi, Deputy Assistant Administrator. [FR Doc. 2015–19173 Filed 8–4–15; 8:45 am] By order of the Commission. Issued: July 30, 2015. Lisa R. Barton, Secretary to the Commission. ACTION: compliance with state and local laws, and reviewing the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of gamma hydroxybutyric acid (2010), a basic class of controlled substance listed in schedule I. The company plans to manufacturer the listed controlled substance for distribution to its customers. PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 Attn: OMB Desk Officer for DOL–WHD, Office of Management and Budget, Room 10235, 725 17th Street, NW., Washington, DC 20503; by Fax: 202– 395–5806 (this is not a toll-free number); or by email: OIRA_ submission@omb.eop.gov. Commenters are encouraged, but not required, to send a courtesy copy of any comments by mail or courier to the U.S. Department of Labor-OASAM, Office of the Chief Information Officer, Attn: Departmental Information Compliance Management Program, Room N1301, 200 Constitution Avenue NW., Washington, DC 20210; or by email: DOL_PRA_PUBLIC@dol.gov. FOR FURTHER INFORMATION CONTACT: Contact Michel Smyth by telephone at 202–693–4129, TTY 202–693–8064, (these are not toll-free numbers) or sending an email to DOL_PRA_ PUBLIC@dol.gov. SUPPLEMENTARY INFORMATION: This ICR seeks approval under the PRA for revisions to the Application for a Farm Labor Contractor or Farm Labor Contractor Employee Certificate of Registration information collection. Migrant and Seasonal Agricultural Worker Protection Act (MSPA) section 101 provides that no individual may perform farm labor contracting activities without a certificate of registration. See 29 U.S.C. 1811. Form WH–530 is the application form that provides the DOL with the information necessary to issue certificates specifying the farm labor contracting activities authorized. In addition, certain vehicle and safety standards are required of a farm labor contractor applicant and such data is collected via forms WH–514, WH–514a, and WH–515. This information collection has been classified as a revision, because DOL proposes to implement minor changes to Forms WH–514, WH–514a, WH–515 and WH– 530. Most of the alterations are to make the forms clearer for the regulated community and to highlight certain instructions. MSPA sections 102, 105, and 511 authorize this information collection. See 29 U.S.C. 1812, 1815, and 1861. This information collection is subject to the PRA. A Federal agency generally cannot conduct or sponsor a collection of information, and the public is generally not required to respond to an information collection, unless it is approved by the OMB under the PRA and displays a currently valid OMB Control Number. In addition, notwithstanding any other provisions of law, no person shall generally be subject to penalty for failing to comply with a collection of information that does not E:\FR\FM\05AUN1.SGM 05AUN1

Agencies

[Federal Register Volume 80, Number 150 (Wednesday, August 5, 2015)]
[Notices]
[Page 46604]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-19173]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Manufacturer of Controlled Substances Registration: Patheon 
Pharmaceuticals, Inc.

ACTION: Notice of registration.

-----------------------------------------------------------------------

SUMMARY: Patheon Pharmaceuticals, Inc. applied to be registered as a 
manufacturer of a certain basic class of controlled substance. The Drug 
Enforcement Administration (DEA) grants Patheon Pharmaceuticals, Inc. 
registration as a manufacturer of this controlled substance.

SUPPLEMENTARY INFORMATION: By notice dated March 9, 2015, and published 
in the Federal Register on March 24, 2015, 80 FR 15632, Patheon 
Pharmaceuticals, Inc., 2110 E. Galbraith Road, Cincinnati, Ohio 45237 
applied to be registered as a manufacturer of a certain basic class of 
controlled substance. No comments or objections were submitted for this 
notice.
    The DEA has considered the factors in 21 U.S.C. 823(a) and 
determined that the registration of Patheon Pharmaceuticals, Inc. to 
manufacture the basic class of controlled substance is consistent with 
the public interest and with United States obligations under 
international treaties, conventions, or protocols in effect on May 1, 
1971. The DEA investigated the company's maintenance of effective 
controls against diversion by inspecting and testing the company's 
physical security systems, verifying the company's compliance with 
state and local laws, and reviewing the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above-named company is granted registration as a bulk 
manufacturer of gamma hydroxybutyric acid (2010), a basic class of 
controlled substance listed in schedule I.
    The company plans to manufacturer the listed controlled substance 
for distribution to its customers.

    Dated: July 29, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-19173 Filed 8-4-15; 8:45 am]
 BILLING CODE P